Oncology Medical News about Metastatic Disease

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node
Annals of Surgical Oncology, 06/18/09

Jakub JW et al. - In a study to determine whether an individual with metastatic disease confined to the sentinel lymph nodes (SLNs) would have a better prognosis than individuals with metastatic disease that has spread to the non-SLNs, regardless of the number of nodes involved, it was found that the number of regional nodes involved with metastatic disease does not affect disease-free survival (DFS) and overall survival (OS) if disease is confined to the SLNs. Consideration should be given to specifying SLN vs non-SLN involvement in the American Joint Committee on Cancer staging manual.

Methods

The study group consists of 229 melanoma pts with a positive SLN who underwent regional nodal dissection.
Cox proportional hazard regression models were used to assess association of the number of SLNs and non-SLNs involved with disease with OS and DFS.

Results

DFS and OS were unchanged regardless of how many SLNs were positive, as long as all disease was confined to SLNs.
Among 183 pts without involvement of non-SLNs, OS remained the same despite an increasing number of SLNs involved.
This was true after controlling for ulceration, Breslow depth, age, sex, and adjuvant treatment.
Once disease was present beyond the SLN, DFS and OS were negatively affected.
Among pts with involvement of non-SLNs, there was no statistically significant association between number of positive SLNs and survival.
Risk of mortality increased with number of non-SLNs involved with metastatic disease.

<< Previous
Patterns of pain and distress during high-dose-rate intracavity...

Next >>
Therapeutic Potential of "Rexinoids" in Cancer Prevention and...

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/09 Relevance Score: 68%

Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
The Oncologist, 10/30/09 Relevance Score: 67%

Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease
Current Opinion in Ophthalmology, 10/27/09 Relevance Score: 67%

Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients
American Journal of Clinical Oncology, 10/06/09 Relevance Score: 67%

Cetuximab-based treatment of metastatic anal cancer: Correlation of response with KRAS mutational status
Oncology (Karger), 11/18/09 Relevance Score: 66%